Study of LY4006896 in healthy people and those with Parkinson's
Part of Brain & nervous system clinical trials.
This study tests an injectable antibody called LY4006896, first in healthy volunteers and then in people with Parkinson's disease. It aims to see if the drug is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old.
- You have been diagnosed with Parkinson's disease using standard criteria.
- You have a body mass index (BMI) between 18 and 34.
- If you take Parkinson's medication, your dose has been stable for at least 90 days and probably won't change for a year.
- You do not have a deep brain stimulation (DBS) implant or other implanted neurostimulation device.
- You do not have serious or unstable health conditions that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study tests a new drug called HL-400 for the first time in people. It checks how safe the drug is and how the body handles it, to see if it could be developed for future patients.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.